Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.32 |
| ▸ | CDC25B | P30305 | 4/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553048 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL20477154 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL27086511 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL29727834 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL17712276 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| Maleic Acid SCHEMBL20552110 | 0.94 | TMPRSS2 (0.36) | PDE2ATMPRSS2HSPA5PTPN1CDC25B | |
| SCHEMBL24158032 | 0.92 | PDE2A (0.38) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL22646505 | 0.92 | PDE2A (0.38) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL14817042 | 0.92 | HSPA5 (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL12393267 | 0.91 | PDE2A (0.35) | PDE2AHTR1AHSPA5PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612614-B2 | Isomorphs of Remdesivir and methods for synthesis of same | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2023-03-28 | — | — | US | claimed |
| US-20210228605-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2021-07-29 | — | — | US | claimed |
| US-20210161927-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2021-06-03 | — | — | US | claimed |
| CN-113493480-B | Preparation and analysis method of Ruidexivir isomer | 南京正大天晴制药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-111542531-B | Substituted nucleosides, nucleotides and analogues thereof | 詹森生物制药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11612614-B2 | Isomorphs of Remdesivir and methods for synthesis of same | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2023-03-28 | — | — | US | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011035250-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2009132135-A1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | PDE2A 4326/4885TMPRSS2 3973/4885HTR1A 4710/4885 |
| US-11612614-B2 | Isomorphs of Remdesivir and methods for synthesis of same | MTAP, SARS1, PNP | PDE2A 782/4885TMPRSS2 94/4885HTR1A 1676/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | PDE2A 3746/4885TMPRSS2 12/4885HTR1A 2011/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | PDE2A 1863/4885TMPRSS2 433/4885HTR1A 2570/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | PDE2A 2899/4885TMPRSS2 1945/4885HTR1A 588/4885 |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | PDE2A 610/4885TMPRSS2 867/4885HTR1A 2398/4885 |
| US-20210228605-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | MTAP, SARS1, PNP | PDE2A 767/4885TMPRSS2 100/4885HTR1A 1687/4885 |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, CDA | PDE2A 2568/4885TMPRSS2 4673/4885HTR1A 623/4885 |
| US-20210161927-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | MTAP, SARS1, PNP | PDE2A 782/4885TMPRSS2 94/4885HTR1A 1676/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | PDE2A 3717/4885TMPRSS2 14/4885HTR1A 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.